Avicanna Inc
🇨🇦XTSE.AVCNCanadaHealthcare
PriceCA$0.110.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 2
- Medium: 2
- Low: 0
Effective tax rate: a sudden drop below its trailing quarter average
Leverage ratio: a sudden drop below its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA05368K1003
- CUSIP
- 05368K100
Company
- Employees
- 87
- Headquarters
- Toronto, Canada
- Website
- https://www.avicanna.com
Market
- Shares outstanding
- 117.8M
- Market cap
- CA$12.96M
Highlights
No high and low reported for today's session.
- Market cap
- CA$12.96M
- EPS LTM
- -CA$0.01calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -10.11calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$25.37M+2%up year on year
- Net income
- -CA$1.28M+80.44%up year on year
- Gross margin
- 53.56%+24.29%up year on year
- Free cash flow
- -CA$1.19M-99.09%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Avicanna Inc is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker AVCN. Its market capitalisation is CA$12.96M, from 117.8M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$0.09 and CA$0.30, and the last close of CA$0.11 sits 10% of the way up that range. The company is headquartered in Toronto, Canada, and employs about 87 people. The same company also trades as 0NN on Frankfurt Stock Exchange.
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.